FTC Reaches Second Insulin Pricing Settlement: Comparing the Caremark and ESI Orders

The FTC settled its second major insulin pricing case against Caremark, requiring PBMs to delink rebates from formulary placement, cap patient out-of-pocket costs, and provide transparent cost reporting. The order mirrors an earlier ESI settlement but carves out Medicare, Medicaid, and Exchange plans from key requirements.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.